Major articleDistribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial
Section snippets
Bacterial isolates
Isolates were collected between January 2004 and September 2005 from 76 medical centers within the 9 census regions across the United States: Pacific (5 centers), Mountain (4 centers), West North Central (5 centers), East North Central (12 centers), Middle Atlantic (14 centers), New England (6 centers), South Atlantic (17 centers), East South Central (6 centers), and West South Central (7 centers). Medical centers were selected based on demographic and geographic diversity, and all centers
E faecalis
Of the 740 E faecalis isolates collected as part of the T.E.S.T. study, a total of 35 (4.7%) were identified as vancomycin resistant. These 35 isolates were collected from 8 of the 9 census regions (none collected from the Pacific region; Fig 1).
Enterococcus faecium
A total of 280 isolates of E faecium were collected across the United States, of which 67.9% were vancomycin resistant. Vancomycin-resistant E faecium were identified in each of the census regions, ranging from 45.5% (New England) to 85.3% (East South
Discussion
The percentage of resistant organisms, such as VRE, MRSA, and penicillin-nonsusceptible S pneumoniae, has been tracked by surveillance studies both in the United States and globally for more than a decade. Such continued surveillance is vital because the presence of an infection caused by MRSA and VRE has been shown to result in increased mortality, length of stay, and hospital costs when compared with infections caused by susceptible organisms.8, 9, 10, 11, 12, 13
This T.E.S.T. study adds to
References (27)
Mechanisms of action of newer antibiotics for gram-positive pathogens
Lancet Infect Dis
(2005)- et al.
Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia
Diagn Microbiol Infect Dis
(2005) - et al.
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY antimicrobial surveillance program (North America, 2001)
Int J Antimicrob Agents
(2004) - et al.
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia
Diagn Microbiol Infect Dis
(2005) - et al.
Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox annual appraisal of potency and spectrum (ZAAPS) program
Int J Antimicrob Agents
(2005) - et al.
Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents
Int J Antimicrob Agents
(2005) - et al.
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project
Diagn Microbiol Infect Dis
(2005) Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment
Clin Infect Dis
(2006)Tigecycline—the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline
J Chemother
(2005)- et al.
Tigecycline: a novel glycylcycline antibiotic
Expert Rev Anti Infect Ther
(2006)
National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, document M7-A6
Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing, document M100-S15
Cited by (14)
Hollow mesoporous hydroxyapatite nanostructures; smart nanocarriers with high drug loading and controlled releasing features
2018, International Journal of PharmaceuticsCitation Excerpt :Local drug delivery systems are of much importance because of their potential for localized and maximum delivery of antibiotics to targeted site to avoid systemic toxicity (Price et al., 1996; Ginebra et al., 2006; Somayaji et al., 1998). Antibiotic resistance (ABR) is a worldwide problem and many literature reports proposed that it has been expanding dramatically and influencing the whole world (Denys et al., 2007; Johnson et al., 2005). A large number of antibacterial agents have been studied for treatment of OM (Nandi et al., 2009).
Susceptibility to Tigecycline and Linezolid Among Gram-Positive Isolates Collected in the United States as Part of the Tigecycline Evaluation and Surveillance Trial (TEST) Between 2004 and 2009
2011, Clinical TherapeuticsCitation Excerpt :The overall rate of MRSA reported by this study is similar to that reported by Tillotson et al10 for isolates from skin and wound sources collected in 2007 (57.8%) and Styers et al11 for isolates collected in 2005 (53.3%). In their report, Denys et al2 for the early part of the TEST program also reported a similar rate (52.0%, 2004–2005), although it should be noted that the isolates are also included in this analysis. The distribution of MRSA rates by region was also similar to that described by Tillotson et al10 in both studies; the highest rates of MRSA were reported for the East South Central region and the lowest for the New England region.
Hospital-level antibacterial prescribing and its completeness in ethiopia: Did it adhere to good prescribing practice?
2020, International Journal of General MedicinePhenotypic and genetic characterization of multidrug-resistant Staphylococcus aureus in the tropics of Southeast Asia
2016, Microbiology (United Kingdom)Antibiotic resistance in Enterococcus faecium clinical isolates
2014, Expert Review of Anti-Infective TherapyResistance pattern of ciprofloxacin against different pathogens
2010, Oman Medical Journal
Supported by Wyeth Pharmaceuticals and by Micron Research Ltd. with editorial support and assistance with data analysis.
Statement of proprietary interest: Gerald A. Denys and Kim M. Koch have no proprietary interest. Michael J. Dowzicky is an employee of Wyeth Pharmaceuticals.